Clofazimine pharmacokinetics in patients with TB: dosing implications | Zendy

Mahmoud Tareq Abdelwahab | Zendy; Sean Wasserman | Zendy; James C. M. Brust | Zendy; Neel R. Gandhi | Zendy; Graeme Meintjes | Zendy; Daniel E. Everitt | Zendy; Andreas H. Diacon | Zendy; Rodney Dawson | Zendy; Lubbe Wiesner | Zendy; Elin M. Svensson | Zendy; Gary Maartens | Zendy; Paolo Denti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clofazimine pharmacokinetics in patients with TB: dosing implications

Author(s) -

Mahmoud Tareq Abdelwahab,

Sean Wasserman,

James C. M. Brust,

Neel R. Gandhi,

Graeme Meintjes,

Daniel E. Everitt,

Andreas H. Diacon,

Rodney Dawson,

Lubbe Wiesner,

Elin M. Svensson,

Gary Maartens,

Paolo Denti

Publication year - 2020

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkaa310

Subject(s) - clofazimine , dosing , pharmacokinetics , medicine , pharmacology , antibacterial agent , antibiotics , intensive care medicine , biology , leprosy , microbiology and biotechnology , immunology

Clofazimine is in widespread use as a key component of drug-resistant TB regimens, but the recommended dose is not evidence based. Pharmacokinetic data from relevant patient populations are needed to inform dose optimization.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research